non-Hodgkin lymphoma

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

Representation on cellular level of lymphoma

Approvals extend use of Roche, AbbVie drugs in lymphoma

Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.

News

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.

News

Approval moves Columvi earlier in DLBCL treatment pathway

Roche has claimed a first-in-class approval in the EU for Columvi in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

News

Regeneron tries again with lymphoma bispecific in US

Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.

News

After FDA no, Regeneron gets yes from EU on odronextamab

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US.

FDA starts priority review of BeOne's Venclexta rival

Approvals extend use of Roche, AbbVie drugs in lymphoma

NICE backs Roche's non-Hodgkin lymphoma drug Columvi

Approval moves Columvi earlier in DLBCL treatment pathway

Regeneron tries again with lymphoma bispecific in US

After FDA no, Regeneron gets yes from EU on odronextamab

Veraxa says delayed US listing is back on track

How to meet your physicians where they are online

non-Hodgkin lymphoma

Editor's Picks